Progress in complete androgen blockade.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 9074904.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complete androgen blockade (CAB) has been shown to increase the survival of patients with symptomatic advanced prostate cancer in three large well-conducted trials compared with castration alone. However, several smaller trials found no survival advantage with CAB. A recent meta-analysis of 22 trials of CAB involving over 5,000 patients showed a non-significant improvement in survival with CAB over castration, but had a number of methodological weaknesses, whereas a sensitivity analysis of published data showed a clear survival benefit. It is hoped that the results of a very large well-designed trial by the National Cancer Institute Intergroup (NCI INT-0105), in which 1,347 men have been randomised to orchidectomy plus flutamide (Eulexin, Schering-Plough International) or orchidectomy plus placebo will provide the definitive answer to this continuing controversy.
Medical subject headings
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Prostatic Neoplasms